Therapeutic DNA Vaccine Company Inovio Biomedical Corp. Announces 'Clinical Trials Update' Conference Call on Jan. 29

Get paid to drive your car:
Earn up to $3,200 a Month driving your Car
Get a FREE Car, Get Paid to Drive your Car.

Four Tier Download FourTierAnnihilation.com
Ebook from Alex Goad, Creator of Google Payload.
Learn How To Avoid Ebay Scams! This Book Is Virtually The A - Z
of How To Use EBAY, Basics, and In-Depth Advanced Strategies that will Motivate YOU!

Set Up A Complete Health Internet Business With Fully-Operational E-Sales Manager To Close Sales Automatically
Has Multiple Income Streams

Disney World Vacation And Savings Travel Guide -- LOOK! Ex-Disney Employee Reveals Insider Secrets.

SAN DIEGO (Business Wire EON) January 24, 2008 -- A replay of the conference call will be available through February 5, 2008, by dialing toll-free (877) 660-6853 in the U.S. and Canada, and (201) 612-7415 outside the U.S. and Canada, and entering both the account #286 and the conference ID #271013.

About Inovio Biomedical Corporation

Inovio Biomedical (AMEX:INO) is a leader in developing human applications of its electroporation technology, which uses brief, controlled electrical pulses to increase cellular uptake of DNA vaccines. Interim human data has shown that Inovio's DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans and that results from one study may necessarily not be reflected or supported by the results of other similar studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2006, our 10-Q for the nine months ended September 30, 2007, and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.

Privacy: Personal Information is not collected on this site at this time. If it were, it would be kept strictly confidential and are not given or sold to any third parties. For more Info, please contact Site Owner: (admin at websurfer.ca) Site Copyright 2007 Netbuy Consulting Corp, Guelph, Ontario, N1C 1B8, Canada.
Phone: 905 -- 580--4892. This privacy policy is here to protect you. Please contact us with any questions. About us: This site is maintained for information purposes only. Please contact us if you have any concerns, we strive to ensure a private and safe web experience. Contact us via email anytime - Thanks!